statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	292
IT - Italia	222
IE - Irlanda	74
DE - Germania	66
SG - Singapore	60
SE - Svezia	44
HK - Hong Kong	37
IN - India	34
BR - Brasile	28
CN - Cina	25
CA - Canada	24
RU - Federazione Russa	19
FR - Francia	17
VN - Vietnam	15
GB - Regno Unito	14
KR - Corea	13
PK - Pakistan	12
IR - Iran	11
MY - Malesia	11
FI - Finlandia	10
JP - Giappone	10
TR - Turchia	10
ZA - Sudafrica	10
PE - Perù	9
UA - Ucraina	9
BD - Bangladesh	8
ID - Indonesia	8
AU - Australia	7
CZ - Repubblica Ceca	7
CL - Cile	6
PL - Polonia	6
NG - Nigeria	5
NL - Olanda	5
PH - Filippine	5
TW - Taiwan	5
ES - Italia	4
MO - Macao, regione amministrativa speciale della Cina	4
AT - Austria	3
GR - Grecia	3
LT - Lituania	3
TH - Thailandia	3
AR - Argentina	2
BJ - Benin	2
EG - Egitto	2
MX - Messico	2
SN - Senegal	2
AE - Emirati Arabi Uniti	1
AL - Albania	1
BE - Belgio	1
BG - Bulgaria	1
CH - Svizzera	1
DO - Repubblica Dominicana	1
EC - Ecuador	1
IQ - Iraq	1
KE - Kenya	1
KH - Cambogia	1
MK - Macedonia	1
MT - Malta	1
NI - Nicaragua	1
NO - Norvegia	1
RO - Romania	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
SR - Suriname	1
TT - Trinidad e Tobago	1
VE - Venezuela	1
Totale	1.188

Nome	#
Midterm functional sequelae and implications in rehabilitation after COVID19. A cross-sectional study	332
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients	206
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19	152
Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge	120
Mid-term Psychiatric Outcomes of Patients Recovered From COVID-19 From an Italian Cohort of Hospitalized Patients	114
Intimate Partner Homicide Suicide: a Mini-Review of the Literature (2012–2018)	92
“Gut–brain axis”: Review of the role of the probiotics in anxiety and depressive disorders	85
Acute Onset Psychosis With Mystical Delusions in a Young Male Patient Following Discontinuation of Corticosteroid Therapy: A Case Report	64
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib	56
Totale	1.221

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	52	0	0	0	0	0	7	4	8	8	13	8	4
2021/2022	152	17	5	6	18	9	17	20	5	15	9	12	19
2022/2023	214	12	18	14	5	13	21	13	6	72	8	15	17
2023/2024	255	9	11	2	5	19	21	46	38	18	33	25	28
2024/2025	251	5	11	12	12	7	19	40	41	34	8	14	48
2025/2026	270	44	29	23	76	68	30	0	0	0	0	0	0
Totale													1.221